Top 10 prostate cancer articles and videos of 2024

There has been a lot of news about prostate cancer over the past year. To celebrate these breakthroughs, the editorial staff at Urology Times® are showcasing our top content on prostate cancer from 2024.

Dr. Hougen on adding a coefficient for Black race to the 4Kscore

In this video, Helen Y. Hougen, MD, shares the background and findings from the study, “Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.” Watch the video here

Dr. Murphy on increasing diversity in cancer clinical trials

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer. Listen to the episode here

Decipher prostate test receives high evidence rating in NCCN guidelines

The Decipher Prostate Genomic Classifier has received a Level 1B evidence rating, the highest rating among molecular tests, in the 2024 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, according to a news release by Veracyte, the developer of the test. Learn more here

Relugolix plus radiotherapy shows safety, efficacy in prostate cancer

Relugolix (Orgovyx) in combination with radiotherapy was found to be safe and efficacious in the treatment of men with localized or advanced prostate cancer, according to a post hoc analysis of 2 randomized clinical trials published in JAMA Oncology. Read more here

FDA grants clearance to IND application for prostate cancer immunotherapy

The FDA has accepted an investigational new drug (application for FK-PC101, a personalized prostate cancer immunotherapy for the treatment of patients with a high risk of recurrence following radical prostatectomy, announced Theragent in a news release. Learn more here

FDA clears IND for 225Ac-J591 in advanced prostate cancer

The FDA has granted clearance to an investigational new drug (application for 225Ac-J591 (CONV01-α), a prostate-specific membrane antigen-targeted monoclonal antibody under investigation for the treatment of patients with advanced prostate cancer, announced Convergent Therapeutics, the developer of the therapy, in a news release. Read more here

AUA releases guideline on salvage therapy in prostate cancer

The American Urological Association, in collaboration with American Society for Radiation Oncology and the Society of Urologic Oncology, has released the 2024 clinical practice guideline on salvage therapy in prostate cancer, the AUA announced in a news release. Learn more here

CMS payment rate established for ArteraAI prostate cancer test

The Centers for Medicare & Medicaid Services have established a payment rate for the ArteraAI prostate cancer test, a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes of treatment in patients with localized prostate cancer, according to a news release from ArteraAI, the developer of the test. Read more here

Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC

Apalutamide (Erleada) was found to provide a significant improvement in overall survival at 24 months compared with enzalutamide (Xtandi) in the treatment of androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer, according to data from a head-to-head retrospective analysis presented at the 6th European Congress of Oncology Pharmacy in Lisbon, Portugal. Learn more here

Active surveillance yields similar outcomes to prostate cancer treatment, 10-year data show

Long-term data recently published in JAMA indicate that active surveillance is an effective alternative to immediate surgery or radiation for patients with favorable-risk prostate cancer. Read more here